Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients

International Journal of Clinical Oncology

Volumn 10, Issue 3, 2005, Pages 182-186

  Miyoshi, Yasuhide ^a   Uemura, Hiroji ^a   Nakamura, Masafumi ^a   Hasumi, Hisashi ^a   Sugiura, Shinpei ^a   Makiyama, Kazuhide ^a   Nakaigawa, Noboru ^a   Kishida, Takeshi ^a   Ogawa, Takehiko ^a   Yao, Masahiro ^a   Kubota, Yoshinobu ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Androgen independent prostate cancer; Docetaxel; Hormone refractory prostate cancer; Taxane; Taxotere

Indexed keywords

ALANINE AMINOTRANSFERASE; ANALGESIC AGENT; ANDROGEN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; GONADORELIN; GRANULOCYTE COLONY STIMULATING FACTOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALGESIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DISEASE COURSE; DRUG EFFECT; ENZYME BLOOD LEVEL; FEVER; FOLLOW UP; HAIR LOSS; HUMAN; JAPAN; LEG EDEMA; LEUKOPENIA; MALE; MOON FACE; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; SENSORY NEUROPATHY; SPINAL CORD INJURY; STATISTICAL ANALYSIS; TISSUE LEVEL;

ADENOCARCINOMA; AGED; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 21644469860     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-005-0490-0     Document Type: Article

References (25)

1. SL Parker T Tong S Bolden 1997 Cancer statistics, 1997 CA Cancer J Clin 47 5 27
2. Vital Statistics of Japan, Statistics and Information Department. Tokyo: Minister's Secretariat, Ministry of Health, Labor and Welfare
3. C Huggins C Hodges 1941 Studies on prostatic cancer I: the effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 293 297
4. EJ Small NJ Vogelzang 1997 Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm J Clin Oncol 15 382 388
5. WK Oh PW Kantoff 1998 Management of hormone refractory prostate cancer: current standards and future prospects J Urol 160 1220 1229
6. ML Slevin L Stubbs HJ Plant 1990 Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public BMJ 300 1458 1460
7. IF Tannock D Osoba MR Stockler 1996 Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1756 1764
8. PW Kantoff S Halabi M Conaway 1999 Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17 2506 2513
9. JF Diaz JM Andreu 1993 Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition Biochemistry 32 2747 2755
10. S Haldar A Basu CM Croce 1997 Bcl2 is the guardian of microtubule integrity Cancer Res 57 229 233
11. W Kreis DR Budman A Calabro 1997 Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines Br J Urol 79 196 202
12. JF Williams HJ Muenchen JM Kamradt 2000 Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study Prostate 44 275 278
13. J Picus M Schultz 1999 Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results Semin Oncol 26 14 18
14. W Berry S Dakhil MA Gregurich 2001 Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate Semin Oncol 28 8 15
15. TM Beer WC Pierce BA Lowe 2001 Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer Ann Oncol 12 1273 1279
16. IF Tannock R de Wit WR Berry 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502 1512
17. DP Petrylak R Macarthur J O'Connor 1999 Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer Semin Oncol 26 28 33
18. DP Petrylak RB Macarthur J O'Connor 1999 Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer J Clin Oncol 17 958 967
19. W Kreis DR Budman J Fetten 1999 Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma Ann Oncol 10 33 38
20. DP Petrylak CM Tangen MH Hussain 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513 1520
21. Japanese Urological Association and The Japanese Society of Pathology 2001 General rule for clinical and pathological studies on prostate cancer 3 Kanehara Tokyo
22. I Tannock M Gospodarowicz W Meakin 1989 Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response J Clin Oncol 7 590 597
23. RE Millikan 1999 Chemotherapy of advanced prostatic carcinoma Semin Oncol 26 185 191
24. M Hussain DC Smith BF El-Rayes 2003 Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer Urology 61 774 780
25. T Kojima T Shimazui M Onozawa 2004 Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients Jpn J Clin Oncol 34 137 141